Fusarium species are versatile pathogens that can cause a wide range of infections in humans, from superficial to disseminated infections. In immunocompromised patients, particularly those with hematologic malignancies and severe neutropenia, Fusarium infections are often life-threatening and have a high mortality rate. The most common species causing infections in immunocompromised patients are *Fusarium solani* (50%), *Fusarium oxysporum* (20%), and *Fusarium verticillioides* and *Fusarium moniliforme* (10% each). These infections can affect various organs, including the lungs, sinuses, skin, and central nervous system, and often present with disseminated disease. The diagnosis of fusariosis relies on clinical suspicion, laboratory cultures, and molecular methods. Treatment options include surgical debridement, antifungal agents such as amphotericin B and voriconazole, and combination therapy. Prevention strategies focus on reducing exposure to Fusarium spp., particularly in immunocompromised patients, and managing underlying conditions to minimize immunosuppression. The prognosis for fusariosis is poor, especially in patients with persistent immunodeficiency, and early and aggressive treatment is crucial for improving outcomes.Fusarium species are versatile pathogens that can cause a wide range of infections in humans, from superficial to disseminated infections. In immunocompromised patients, particularly those with hematologic malignancies and severe neutropenia, Fusarium infections are often life-threatening and have a high mortality rate. The most common species causing infections in immunocompromised patients are *Fusarium solani* (50%), *Fusarium oxysporum* (20%), and *Fusarium verticillioides* and *Fusarium moniliforme* (10% each). These infections can affect various organs, including the lungs, sinuses, skin, and central nervous system, and often present with disseminated disease. The diagnosis of fusariosis relies on clinical suspicion, laboratory cultures, and molecular methods. Treatment options include surgical debridement, antifungal agents such as amphotericin B and voriconazole, and combination therapy. Prevention strategies focus on reducing exposure to Fusarium spp., particularly in immunocompromised patients, and managing underlying conditions to minimize immunosuppression. The prognosis for fusariosis is poor, especially in patients with persistent immunodeficiency, and early and aggressive treatment is crucial for improving outcomes.